Pediatric infectious diseases — Quo vadis 2015?

  • David Nadal
Part of the Birkhäuser Advances in Infectious Diseases book series (BAID)


In modern medicine the discipline pediatric infectious diseases is an essential medical specialty. The challenging and complex tasks in the next years include meticulous consolidation and careful extension of existing activities aiming at conducting high level research, offering high standard teaching, and providing high quality patient management. This can only be accomplished by exquisitely dedicated individuals with extraordinary communication and integrative skills following painstaking continued training and formation. Potential careers in the discipline can be envisioned not only in academics, but also in government, public health, and industry, whilst less likely in private practice.


Severe Acute Respiratory Syndrome Chronic Granulomatous Disease Severe Acute Respiratory Syndrome Infectious Disease Specialist Pediatric Infectious Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Potocki M, Goette J, Szucs TD, Nadal D (2003) Prospective survey of antibiotic utilization in pediatric hospitalized patients to identify targets for improvement of prescription. Infection 31: 398–403PubMedGoogle Scholar
  2. 2.
    Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M (2001) The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 344: 889–896PubMedCrossRefGoogle Scholar
  3. 3.
    Plasschaert AI, Rovers MM, Schilder AG, Verheij TJ, Hak E (2006) Trends in doctor consultations, antibiotic prescription, and specialist referrals for otitis media in children: 1995–2003. Pediatrics 117: 1879–1886PubMedCrossRefGoogle Scholar
  4. 4.
    Peter G (1995) The pediatric infectious disease physician: current roles and importance of the specialty in the care of children. Strategic Development and Long-Range Planning Committee, Pediatric Infectious Diseases Society. Pediatr Infect Dis J 14: 900–903PubMedCrossRefGoogle Scholar
  5. 5.
    Chatterjee A, Lackey SJ (2001) Prospective study of telephone consultation and communication in pediatric infectious diseases. Pediatr Infect Dis J 20: 968–972PubMedCrossRefGoogle Scholar
  6. 6.
    Sandora TJ, Goldmann DA (2005) Medical errors detected and corrected by a pediatric infectious diseases consultation service. Infect Control Hosp Epidemiol 26: 417–420PubMedCrossRefGoogle Scholar
  7. 7.
    Boyle MP, Farukhi Z, Nosky ML (2001) Strategies for improving transition to adult cystic fibrosis care, based on patient and parent views. Pediatr Pulmonol 32: 428–436PubMedCrossRefGoogle Scholar
  8. 8.
    Urschel S, Ramos J, Mellado M, Giaquinto C, Verweel G, Schuster T, Niehues T, Belohradsky B, Wintergerst U; European PCP-withdrawal Study Group (2005) Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS 19: 2103–2108PubMedCrossRefGoogle Scholar
  9. 9.
    Rappuoli R (2004) From Pasteur to genomics: progress and challenges in infectious diseases. Nat Med 10: 1177–1185PubMedCrossRefGoogle Scholar
  10. 10.
    Kind C, Rudin C, Siegrist CA, Wyler CA, Biedermann K, Lauper U, Irion O, Schupbach J, Nadal D (1998) Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS 12: 205–210PubMedCrossRefGoogle Scholar
  11. 11.
    Blanche S, Tardieu M, Rustin P, Slama A, Barret B, Firtion G, Ciraru-Vigneron N, Lacroix C, Rouzioux C, Mandelbrot L et al (1999) Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet 354: 1084–1089PubMedCrossRefGoogle Scholar
  12. 12.
    Busch MP, Kleinman SH, Nemo GJ (2003) Current and emerging infectious risks of blood transfusions. JAMA 289: 959–962PubMedCrossRefGoogle Scholar
  13. 13.
    Roberts L (2004) Polio endgame. Polio: The final assault? Science 303: 1960–1968PubMedCrossRefGoogle Scholar
  14. 14.
    Nathanson N, Fine P (2002) Virology. Poliomyelitis eradication — a dangerous endgame. Science 296: 269–270PubMedCrossRefGoogle Scholar
  15. 15.
    Cassell JA, Leach M, Poltorak MS, Mercer CH, Iversen A, Fairhead JR (2006) Is the cultural context of MMR rejection a key to an effective public health discourse? Public Health 120: 783–794PubMedCrossRefGoogle Scholar
  16. 16.
    Peltola H (2000) Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 13: 302–317PubMedCrossRefGoogle Scholar
  17. 17.
    Poehling KA, Talbot TR, Griffin MR, Craig AS, Whitney CG, Zell E, Lexau CA, Thomas AR, Harrison LH, Reingold AL et al (2006) Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA 295: 1668–1674PubMedCrossRefGoogle Scholar
  18. 18.
    Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM et al (2006) Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 354: 1455–1463PubMedCrossRefGoogle Scholar
  19. 19.
    Rappuoli R (2001) Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 19: 2688–2691PubMedCrossRefGoogle Scholar
  20. 20.
    Danzig L (2006) Reverse vaccinology — in search of a genome-derived meningococcal vaccine. Vaccine 24(Suppl) 2:S2-11–2Google Scholar
  21. 21.
    Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5: 471–484PubMedCrossRefGoogle Scholar
  22. 22.
    Raoult D, Fournier PE, Drancourt M (2004) What does the future hold for clinical microbiology? Nat Rev Microbiol2: 151–159PubMedCrossRefGoogle Scholar
  23. 23.
    Abel L, Casanova JL (2006) Human genetics of infectious diseases: Fundamental insights from clinical studies. Semin Immunol 18: 327–329PubMedCrossRefGoogle Scholar
  24. 24.
    Seger RA, Gungor T, Belohradsky BH, Blanche S, Bordigoni P, Di Bartolomeo P, Flood T, Landais P, Muller S, Ozsahin H et al (2002) Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985–2000. Blood 100: 4344–4350PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag Basel/Switzerland 2007

Authors and Affiliations

  • David Nadal
    • 1
  1. 1.Division of Infectious Diseases and Hospital HygieneUniversity Children’s Hospital of ZurichZürichSwitzerland

Personalised recommendations